Characteristic | Subgroup A: 11 subjects (RAI) | Subgroup B: 11 subjects (PEI + RAI) |
---|---|---|
Age (y) | 61 ± 7 (48–69) | 61 ± 8 (52–75) |
Female/male | 6/5 | 6/5 |
SYS | 3.4 ± 0.9 (2–6) | 3.5 ± 0.8 (2–6) |
Nodule volume (mL) | 53.1 ± 22.3 (34.9–103) | 60.8 ± 29.5 (33.5–112) |
FT4 (pmol/L) | 35.8 ± 12.4 (26.2–54.9) | 33.4 ± 9.4 (18.3–48.6) |
FT3 (pmol/L) | 14.2 ± 5.1 (8.7–23.5) | 13.0 ± 4.3 (6.8–22.5) |
TSH (mU/L) | 0.01 ± 0.00 (0.00–0.01) | 0.01 ± 0.00 (0.00–0.01) |
RAIU (24-h %) | 61.8 ± 11.0 (43.9–77.5) | 53.9 ± 13.9 (42.0–78.3) |
RAI dose (MBq) | 1,048 ± 392 (555–2,035) | 730 ± 245* (444–1,110) |
↵* P < 0.05.
Data are given as mean ± SD, with range in parentheses. Normal ranges were 9–24.5 pmol/L for FT4, 2.9–6.5 pmol/L for FT3, and 0.2–4.0 mU/L for TSH. SYS includes pressure symptoms in neck, dysphagia, and aesthetic complaints.